PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.
作者信息
Melani Christopher, Major Ajay, Schowinsky Jeffrey, Roschewski Mark, Pittaluga Stefania, Jaffe Elaine S, Pack Svetlana D, Abdullaev Zied, Ahlman Mark A, Kwak Jennifer J, Morgan Rustain, Rabinovitch Rachel, Pan Zenggang, Haverkos Bradley M, Gutman Jonathan A, Pollyea Daniel A, Smith Clayton A, Wilson Wyndham H, Kamdar Manali
机构信息
National Cancer Institute, Bethesda, MD.
University of Colorado School of Medicine, Aurora, CO.
出版信息
N Engl J Med. 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767.
Abstract
摘要
相似文献
1
PD-1 Blockade in Mediastinal Gray-Zone Lymphoma.
N Engl J Med. 2017 Jul 6;377(1):89-91. doi: 10.1056/NEJMc1704767.
2
[Not Available].
Bull Cancer. 2016 Nov;103 Suppl 1:S160-S163. doi: 10.1016/S0007-4551(16)30374-5.
3
Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Eur J Cancer. 2017 May;76:1-7. doi: 10.1016/j.ejca.2017.01.033. Epub 2017 Mar 4.
4
Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Blood. 2017 Jul 20;130(3):267-270. doi: 10.1182/blood-2016-12-758383. Epub 2017 May 10.
5
PD-1 Blockers.
Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045.
6
Targeting immune checkpoints in lymphoma.
Curr Opin Hematol. 2015 Jul;22(4):337-42. doi: 10.1097/MOH.0000000000000158.
7
Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Expert Rev Hematol. 2020 Apr;13(4):375-392. doi: 10.1080/17474086.2020.1733405. Epub 2020 Mar 2.
8
PD-1 inhibitors effective in hodgkin lymphoma.
Cancer Discov. 2015 Feb;5(2):102-3. doi: 10.1158/2159-8290.CD-NB2015-002. Epub 2015 Jan 9.
9
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Blood. 2017 Mar 9;129(10):1380-1388. doi: 10.1182/blood-2016-09-738385. Epub 2017 Jan 10.
10
PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Ann Hematol. 2018 Feb;97(2):229-237. doi: 10.1007/s00277-017-3176-6. Epub 2017 Nov 11.
引用本文的文献
1
Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies.
Cancers (Basel). 2024 Dec 15;16(24):4181. doi: 10.3390/cancers16244181.
2
A targeted gene signature stratifying mediastinal gray zone lymphoma into classical Hodgkin lymphoma-like or primary mediastinal B-cell lymphoma-like subtypes.
Haematologica. 2024 Nov 1;109(11):3771-3775. doi: 10.3324/haematol.2024.285266.
3
Anti-PD-1 Therapy in Advanced Pediatric Malignancies in Nationwide Study: Good Outcome in Skin Melanoma and Hodgkin Lymphoma.
Cancers (Basel). 2024 Feb 28;16(5):968. doi: 10.3390/cancers16050968.
4
Evolution of Lymphoma Diagnosis in the Era of Personalized Medicine: A Marriage of Pathology and Genomics for Clinical Practice.
Am J Pathol. 2023 Dec;193(12):1880-1886. doi: 10.1016/j.ajpath.2023.08.012. Epub 2023 Sep 19.
5
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
Haematologica. 2024 Feb 1;109(2):533-542. doi: 10.3324/haematol.2023.283002.
6
[Gray zone lymphoma: five cases report and literature review].
Zhonghua Xue Ye Xue Za Zhi. 2023 Mar 14;44(3):242-246. doi: 10.3760/cma.j.issn.0253-2727.2023.03.011.
7
Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment.
Front Pharmacol. 2023 Mar 7;14:1079924. doi: 10.3389/fphar.2023.1079924. eCollection 2023.
8
Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma.
Blood. 2023 May 4;141(18):2187-2193. doi: 10.1182/blood.2022016590.
9
Zr Immuno-PET Imaging of Tumor PD-1 Reveals That PMA Upregulates Lymphoma PD-1 through NFB and JNK Signaling.
Mol Imaging. 2022 Feb 12;2022:5916692. doi: 10.1155/2022/5916692. eCollection 2022.
10
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma.
Cancer Cell. 2021 Oct 11;39(10):1422-1437.e10. doi: 10.1016/j.ccell.2021.08.011. Epub 2021 Sep 30.
本文引用的文献
1
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
J Clin Oncol. 2016 Aug 10;34(23):2690-7. doi: 10.1200/JCO.2016.66.4482. Epub 2016 Apr 11.
2
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
N Engl J Med. 2015 Jan 22;372(4):311-9. doi: 10.1056/NEJMoa1411087. Epub 2014 Dec 6.
3
A prospective study of mediastinal gray-zone lymphoma.
Blood. 2014 Sep 4;124(10):1563-9. doi: 10.1182/blood-2014-03-564906. Epub 2014 Jul 14.
4
Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations.
Mod Pathol. 2011 Dec;24(12):1586-97. doi: 10.1038/modpathol.2011.116. Epub 2011 Aug 5.
5
Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.
Am J Surg Pathol. 2005 Nov;29(11):1411-21. doi: 10.1097/01.pas.0000180856.74572.73.
Zotero 插件